Sorry, you need to enable JavaScript to visit this website.

dhcf

Department of Health Care Finance - DHCF
 

DC Agency Top Menu

-A +A
Bookmark and Share

Transmittal 23-31 Clarification of Coverage of Over-the-Counter Narcan® Nasal Spray


Tuesday, July 18, 2023

The purpose of this transmittal is to clarify the coverage of Narcan® (4 milligram naloxone hydrochloride nasal spray), following the recent approval by the U.S. Food and Drug Administration (FDA) to allow the sale of the drug without a prescription, or “over-the-counter” (OTC). Narcan® is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.